Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.04 USD
Change Today +0.04 / 2.00%
Volume 35.1K
VRML On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $2.50
52 Week Low
12/9/14 - $1.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians diagnose, treat, and enhance outcomes for women. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company’s lead product is OVA1, a blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices in the United States. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

31 Employees
Last Reported Date: 03/31/15
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $107.3K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $269.0K
Compensation as of Fiscal Year 2014.

vermillion inc (VRML) Key Developments

Vermillion, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Vermillion, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported total product revenue in the second quarter of 2015 was $535,000, as compared to $211,000 in the same year-ago period. This increase is attributable to Vermillion's March 11, 2015 commercial agreement with Quest Diagnostics, which now facilitates recognition of all product revenue at the time an OVA1 test is performed by Quest Diagnostics rather than deferring some revenue as in prior periods. Net loss was $4,849,000 or $0.11 per basic and diluted against $5,555,000 or $0.15 per basic and diluted loss per share. Loss from operations was $4,848,000 against $5,558,000 a year ago. For the six months, the company reported net loss of $8,986,000 or $0.21 per basic and diluted share on total revenue of $1,486,000 against net loss of $9,542,000 or $0.27 per basic and diluted share on total revenue of $629,000 a year ago. Loss from operations was $9,110,000 against $9,553,000 a year ago.

Vermillion, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 10:00 AM

Vermillion, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 10:00 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Vermillion, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Vermillion, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.04 USD +0.04

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.0027 USD -0.0013
Imperial Innovations Group PLC 488.75 GBp +8.75
Jeol Ltd ¥690.00 JPY +5.00
MDxHealth €4.10 EUR 0.00
Miraculins Inc C$0.05 CAD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at